Trial Profile
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2017
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 11 Oct 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 14 Aug 2012 Actual initiation date changed from Apr 2011 to Mar 2011 as reported by ClinicalTrials.gov.
- 14 Aug 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.